Harrow, Inc. (NASDAQ:HROW) Shares Acquired by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. lifted its position in Harrow, Inc. (NASDAQ:HROW - Free Report) by 6.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 664,714 shares of the company's stock after purchasing an additional 41,896 shares during the period. D. E. Shaw & Co. Inc. owned 1.87% of Harrow worth $22,301,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Harrow by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company's stock valued at $62,809,000 after purchasing an additional 5,225 shares during the period. Braidwell LP boosted its holdings in shares of Harrow by 106.3% in the fourth quarter. Braidwell LP now owns 907,039 shares of the company's stock valued at $30,431,000 after purchasing an additional 467,401 shares during the period. Northern Trust Corp boosted its holdings in shares of Harrow by 7.5% in the fourth quarter. Northern Trust Corp now owns 319,084 shares of the company's stock valued at $10,705,000 after purchasing an additional 22,266 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Harrow by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 255,218 shares of the company's stock valued at $8,563,000 after purchasing an additional 3,589 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Harrow by 443.1% in the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock valued at $10,717,000 after purchasing an additional 194,480 shares during the period. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Stock Up 10.9%

Harrow stock traded up $2.79 during mid-day trading on Friday, reaching $28.41. 633,665 shares of the company were exchanged, compared to its average volume of 498,095. The business has a fifty day moving average of $25.02 and a 200 day moving average of $31.91. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The firm has a market cap of $1.04 billion, a P/E ratio of -30.22 and a beta of 0.41. Harrow, Inc. has a 12-month low of $15.97 and a 12-month high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). The company had revenue of $47.83 million for the quarter, compared to analysts' expectations of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. Research analysts anticipate that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on HROW. HC Wainwright boosted their price target on Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a report on Monday, May 12th. B. Riley lowered their target price on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a report on Tuesday, April 1st.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.